Journal of Pharmaceutical Innovation最新文献

筛选
英文 中文
Investigating the Multi-Target Mechanisms of Calycosin-7-O-β-D‑glucoside Against Colorectal Cancer via Integrated Network Pharmacology, Molecular Docking, and In Vitro Experiments 通过综合网络药理学、分子对接和体外实验研究毛蕊花素-7- o -β-D糖苷抗结直肠癌的多靶点机制
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-23 DOI: 10.1007/s12247-026-11051-6
Zhaohuan Li, Jie Xu, Jianjin Guo, Xin Zhang, Jingwen Zhao, Peihan Li, Mingbin Gui, Xin Cheng, Feng Gao
{"title":"Investigating the Multi-Target Mechanisms of Calycosin-7-O-β-D‑glucoside Against Colorectal Cancer via Integrated Network Pharmacology, Molecular Docking, and In Vitro Experiments","authors":"Zhaohuan Li,&nbsp;Jie Xu,&nbsp;Jianjin Guo,&nbsp;Xin Zhang,&nbsp;Jingwen Zhao,&nbsp;Peihan Li,&nbsp;Mingbin Gui,&nbsp;Xin Cheng,&nbsp;Feng Gao","doi":"10.1007/s12247-026-11051-6","DOIUrl":"10.1007/s12247-026-11051-6","url":null,"abstract":"<div><h3>Purpose</h3><p>Colorectal cancer (CRC) is a heterogeneous and drug-resistant malignancy that urgently requires multi-target therapeutic agents. This study aimed to systematically elucidate the multi-target molecular mechanisms of calycosin-7-<i>O</i>-<i>β</i>-D-glucoside (CG), a bioactive flavonoid from <i>Astragali radix</i>, against CRC by integrating computational prediction, dynamic simulation, clinical bioinformatics validation, and in vitro experimental verification.</p><h3>Methods</h3><p>Network pharmacology was employed to predict CG targets and CRC-associated genes, with overlapping targets subjected to PPI network construction, GO/KEGG enrichment analyses, and core target screening. Molecular docking and 100‑ns molecular dynamics (MD) simulation were performed to evaluate binding affinity and complex stability. Multi‑database bioinformatics analyses (HPA, GEPIA, TIMER) validated clinical relevance, prognostic value, and immune infiltration correlations of core targets. In vitro assays, including CCK‑8, TUNEL, EdU, flow cytometry, colony formation, wound healing, Transwell invasion, tumorsphere formation, and Western blotting, were conducted in HCT116 and HT29 cells to confirm CG’s antitumor effects and mechanistic regulation.</p><h3>Results</h3><p>Network pharmacology identified 99 overlapping targets, with ten core targets and significant enrichment in the PI3K‑Akt signaling pathway. Molecular docking revealed strong binding affinities, and MD simulation confirmed long‑term stability of the CG–HSP90AA1 complex. Multi‑database analyses showed core target overexpression in CRC tissues, association with poor prognosis, and correlations with CD8⁺ T cells, Tregs, MDSCs, and neutrophils. In vitro, CG concentration‑dependently suppressed viability, induced apoptosis, inhibited proliferation, migration, invasion, and tumorsphere formation. Western blotting confirmed that CG reduced p‑PI3K/PI3K and p‑Akt/Akt ratios, decreased Bcl‑2/Bax, and activated cleaved caspase‑3, triggering the mitochondrial apoptotic pathway.</p><h3>Conclusion</h3><p>This study is the first to demonstrate that CG exerts anti‑CRC effects through multi‑target binding to HSP90AA1, TNF, and PTGS2, coordinately suppressing the PI3K‑Akt pathway and downstream apoptotic cascades, thereby inhibiting malignant phenotypes and cancer stem cell‑like properties. These findings establish a comprehensive “computational prediction → dynamic simulation → clinical association → experimental validation” paradigm and provide experimental evidence supporting CG as a promising adjuvant therapeutic candidate for CRC.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149035381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spray-Drying-Assisted Development and Characterization of Apomorphine Hydrochloride-Loaded Liposomes for Sustained Subcutaneous Delivery 喷雾干燥辅助下持续皮下递送盐酸阿波啡脂质体的研制和表征
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-22 DOI: 10.1007/s12247-026-11031-w
Raziye Çabuk, Cem Varan, Gamze Varan, Erem Bilensoy
{"title":"Spray-Drying-Assisted Development and Characterization of Apomorphine Hydrochloride-Loaded Liposomes for Sustained Subcutaneous Delivery","authors":"Raziye Çabuk,&nbsp;Cem Varan,&nbsp;Gamze Varan,&nbsp;Erem Bilensoy","doi":"10.1007/s12247-026-11031-w","DOIUrl":"10.1007/s12247-026-11031-w","url":null,"abstract":"<div><h3>Purpose</h3><p>Apomorphine hydrochloride (Apo HCl), a dopaminergic agonist used in advanced Parkinson’s disease, is limited by its short plasma half-life, oxidative instability, and need for frequent subcutaneous dosing. This study aimed to develop a sustained-release liposomal formulation of Apo HCl using a scalable manufacturing-oriented approach. Combining spray-drying-based lipid matrix formation with high-pressure homogenization offers a practical strategy for producing liposomal dispersions designed to protect Apo HCl and provide sustained subcutaneous drug release.</p><h3>Methods</h3><p>Apo HCl-loaded liposomes were prepared by spray drying, hydration and high-pressure homogenization. The effects of lipid composition, cholesterol content, and Apo HCl concentration were evaluated through physicochemical characterization, solid-state analysis, in vitro release, cytocompatibility, and short-term stability studies.</p><h3>Results</h3><p>The selected lead formulation showed a particle size of 112 nm, polydispersity index of 0.14, zeta potential of − 42 mV, and encapsulation efficiency of 99.2%. The liposomal formulation sustained Apo HCl release for up to 48 h, whereas the reference solution released rapidly within 1 h. Blank liposomes maintained L929 cell viability above 70% and showed favorable short-term refrigerated stability.</p><h3>Conclusions</h3><p>The selected lead Apo HCl liposomes represent a promising liposomal platform for sustained subcutaneous delivery and warrant further in vivo evaluation to confirm their pharmacokinetic performance and translational potential.</p><h3>Summary</h3><p>Apomorphine hydrochloride requires frequent administration due to its short duration of action, limiting patient convenience in Parkinson’s disease management. This study developed spray-drying-assisted liposomes for subcutaneous delivery. Lipid matrices were prepared by spray drying, hydrated under acidic and antioxidant-containing conditions, and processed by high-pressure homogenization. The selected lead formulation showed nanosized vesicles, low polydispersity, high encapsulation efficiency, negative zeta potential, and a gradual in vitro release profile within the 48 h study period. Stability and physicochemical characterization supported the suitability of the formulation approach. These findings indicate that Apo HCl liposomes may provide a promising platform for further in vivo evaluation.</p><h3>Teaser</h3><p>This study presents a spray-drying-assisted liposomal formulation designed to sustain apomorphine hydrochloride release and support further evaluation as a subcutaneous sustained-release delivery platform.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149034931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CyberAIDD-Guided Design and Developability-Aware Prioritization of Lapatinib-Inspired Analogues for Breast Cancer 网络辅助指导下的乳腺癌拉帕替尼类似物的设计和可发展性优先排序
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-22 DOI: 10.1007/s12247-026-11071-2
Mitali Kamat, Kiran N. Gaikwad, Sourabh Malabade, B. V. Deepika, Parixit Bhandurge, Sukanya Pote, Harini Patil, Shailaja Nare, Mahesh Palled, Purva Patil
{"title":"CyberAIDD-Guided Design and Developability-Aware Prioritization of Lapatinib-Inspired Analogues for Breast Cancer","authors":"Mitali Kamat,&nbsp;Kiran N. Gaikwad,&nbsp;Sourabh Malabade,&nbsp;B. V. Deepika,&nbsp;Parixit Bhandurge,&nbsp;Sukanya Pote,&nbsp;Harini Patil,&nbsp;Shailaja Nare,&nbsp;Mahesh Palled,&nbsp;Purva Patil","doi":"10.1007/s12247-026-11071-2","DOIUrl":"10.1007/s12247-026-11071-2","url":null,"abstract":"<div><h3>Purpose</h3><p>This study aimed to generate and computationally prioritize lapatinib-inspired analogues with improved predicted EGFR kinase binding, conformational stability, pathway relevance, and developability in the context of breast cancer.</p><h3>Methods</h3><p>An artificial intelligence-assisted platform was used to generate 2,000 lapatinib analogues. The compounds were docked into the ATP-binding site of the human EGFR kinase domain co-crystallized with lapatinib (PDB ID: 1XKK), followed by Prime MM-GBSA rescoring of the top 20 candidates. Four prioritized analogues were subjected to 200 ns molecular dynamics simulations, including RMSD, RMSF, secondary-structure, interaction-persistence, ligand-flexibility, principal component, free-energy landscape, and dynamic cross-correlation analyses. Network pharmacology and GO/KEGG enrichment were used to identify breast cancer-associated targets and pathways. Drug-likeness, pharmacokinetic behaviour, and toxicity were predicted using QikProp, SwissADME, and ADMETlab 3.0.</p><h3>Results</h3><p>P407AM53379 showed the best docking score (-8.7), whereas P407AM21445 exhibited a favourable MM-GBSA estimate of -73.56 kcal/mol. P407AM63960 demonstrated the most balanced dynamic behaviour, with a mean protein Cα RMSD of approximately 1.42 Å, limited residue fluctuations, persistent interactions, compact conformational sampling, and a dominant low-energy basin. Network analysis linked the prioritized compounds with EGFR/ERBB, PI3K-AKT, MAPK, JAK-STAT, mTOR, and resistance-related pathways. However, predicted solubility, hERG, hepatotoxicity, genotoxicity, and molecular-size liabilities remained.</p><h3>Conclusion</h3><p>P407AM63960 emerged as the most dynamically balanced computationally prioritized EGFR-binding hypothesis among the comparable simulated systems. However, the structure-based analyses directly evaluated only the EGFR kinase domain. Chemical synthesis and experimental evaluation against both EGFR and HER2 are therefore required before dual-target activity, selectivity or therapeutic relevance can be established.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149034920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systematic QbD-Assisted RP-HPLC Method Development for Impurity Analysis of Efonidipine Hydrochloride Ethanolate, Chlorthalidone, and Telmisartan in a Single Pill: A Novel Fixed Dose Combination qbd辅助的系统反相高效液相色谱法:一种新的固定剂量组合——盐酸埃福尼地平乙醇酸盐、氯噻酮和替米沙坦的杂质分析
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-22 DOI: 10.1007/s12247-026-11042-7
Anil Gadhe, Atmaram Pawar, Vikram Gharge, Balasaheb Jadhav, Vikas Mohite
{"title":"Systematic QbD-Assisted RP-HPLC Method Development for Impurity Analysis of Efonidipine Hydrochloride Ethanolate, Chlorthalidone, and Telmisartan in a Single Pill: A Novel Fixed Dose Combination","authors":"Anil Gadhe,&nbsp;Atmaram Pawar,&nbsp;Vikram Gharge,&nbsp;Balasaheb Jadhav,&nbsp;Vikas Mohite","doi":"10.1007/s12247-026-11042-7","DOIUrl":"10.1007/s12247-026-11042-7","url":null,"abstract":"<div><h3>Purpose</h3><p>Efonidipine Hydrochloride Ethanolate, Chlorthalidone, Telmisartan, and their associated impurities, Efonidipine Related Compound A and Chlorthalidone Related Compound A, in a fixed-dose combination tablet formulation were developed and validated using an RP-HPLC approach.</p><h3>Methods</h3><p>Method development and optimization was done using a Quality by Design methodology supported by Design of Experiments to ensure systematic optimization and dependable chromatographic performance. Buffer pH and mobile phase composition were determined to be crucial technique parameters based on risk assessment, and a central composite design was used to optimize them. They were statistically assessed for their impact on retention durations of the analytes, resolution between Chlorthalidone and Chlorthalidone Related Compound A, and crucial analytical responses between Telmisartan and Efonidipine Related Compound A.</p><h3>Results</h3><p>With correlation coefficients (R²) falling within the range, predictive models demonstrated great reliability. Gradient elution with phosphate buffer, acetonitrile, and methanol utilizing a Photodiode Array detector produced the best separation. Results demonstrated adequate specificity, accuracy, linearity, precision, sensitivity, and robustness after the method was validated in accordance with ICH criteria. Efonidipine Related Compound A and Chlorthalidone Related Compound A were fully validated for their ability to quantify active pharmaceutical ingredients. Resultant separation of degradation products, analyte, and impurity peaks was confirmed by conducting forced degradation studies under various saturation parameters, showing the stability-indicating nature of the method.</p><h3>Conclusion</h3><p>The developed method can serve for stability studies, impurity profiling, and routine quality control of this triple-drug combination.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149034433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and Evaluation of a Hydroxyurea-loaded Invasome Hydrogel for Enhanced Anti-psoriatic Efficacy and Reduced Systemic Exposure 羟基脲负载侵入体水凝胶增强抗银屑病疗效和减少全身暴露的开发和评价
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-22 DOI: 10.1007/s12247-026-11028-5
Taiba Rizvi, Mayank Garhewal, Khusboo Agrawal, Achal Mishra, Yogesh Vaishnav, Shekhar Verma
{"title":"Development and Evaluation of a Hydroxyurea-loaded Invasome Hydrogel for Enhanced Anti-psoriatic Efficacy and Reduced Systemic Exposure","authors":"Taiba Rizvi,&nbsp;Mayank Garhewal,&nbsp;Khusboo Agrawal,&nbsp;Achal Mishra,&nbsp;Yogesh Vaishnav,&nbsp;Shekhar Verma","doi":"10.1007/s12247-026-11028-5","DOIUrl":"10.1007/s12247-026-11028-5","url":null,"abstract":"<div><p>The purpose of this study was to develop and optimize a new invasome hydrogel to deliver hydroxyurea for treating psoriasis topically and with less systemic side effects from oral administration. The optimization of the hydroxyurea loaded invasomes gel was performed using a 2<sup>3</sup> factorial design by independently varying the phospholipid, ethanol and terpene concentrations. The optimized formulation (F1) had a particle size of 130 ± 0.16 nm; zeta potential of -28.5 ± 0.045 mV; entrapment efficiency of 92.1 ± 0.15%; viscosity of 10,200 ± 0.17 cP. Morphology was confirmed to be spherical with transmission electron microscopy, drug entrapment and partial amorphization were indicated by Fourier-transform infrared spectroscopy and X-ray diffraction. The hydroxyurea-loaded invasome was then combined with a Carbopol 934 gel base to improve skin compatibility. Stability studies found minimal change in entrapment efficiency and particle size. The in vitro drug release was sustained 99.04 ± 1.29% at 24h, skin permeation and retention studies showed 68.7 ± 5.2%, skin deposition and negligible systemic permeation. In vivo evaluation was performed using a psoriasis rat model induced by imiquimod. Hydroxyurea dramatically reduced erythema, scaling and epidermal thickness, though rejuvenating orthokeratosis compared to clobetasol propionate. Hydroxyurea was not detectable in blood which showed minimal systemic exposure, as measured by HPLC.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149034921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Vitro-In Vivo Correlation (IVIVC) of Satranidazole HCl-Loaded Polymeric Nanoparticles for Colon Targeting: A Comprehensive Evaluation 载盐酸萨特硝唑聚合物纳米颗粒结肠靶向的体内外相关性(IVIVC):一项综合评价
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-22 DOI: 10.1007/s12247-026-11070-3
Debgopal Ganguly, Ananta Choudhury, Subhabrota Majumdar
{"title":"In Vitro-In Vivo Correlation (IVIVC) of Satranidazole HCl-Loaded Polymeric Nanoparticles for Colon Targeting: A Comprehensive Evaluation","authors":"Debgopal Ganguly,&nbsp;Ananta Choudhury,&nbsp;Subhabrota Majumdar","doi":"10.1007/s12247-026-11070-3","DOIUrl":"10.1007/s12247-026-11070-3","url":null,"abstract":"<div><h3>Background</h3><p>Colon-targeted drug delivery systems are critical for treating inflammatory bowel disease (IBD) and associated colon cancer. Satranidazole (STZ), a second-generation nitroimidazole, offers therapeutic potential but suffers from poor solubility and early absorption in the upper gastrointestinal tract. This study aimed to develop STZ-loaded polymeric nanoparticles (STZ-Nps) and establish a Level A <i>in vitro</i>-<i>in vivo</i> correlation (IVIVC).</p><h3>Methods</h3><p>STZ-Nps were fabricated using Eudragit RS100 and RL100 via a modified solvent evaporation method. Nine formulations (F1-F9) were evaluated for particle size, zeta potential, polydispersity index (PDI), entrapment efficiency (EE%), and<i> in vitro</i> drug release. The optimized formulation (F3) was administered orally to male Wistar rats (30 mg/kg), and pharmacokinetic parameters were determined using a validated RP-HPLC method. IVIVC was established by correlating <i>in vitro</i> cumulative drug release with <i>in vivo</i> fraction absorbed.</p><h3>Results</h3><p>F3 demonstrated optimal characteristics: particle size 193 nm, zeta potential − 34.25 mV, PDI 0.125, and EE% 83.5 ± 0.5%. <i>In vitro</i> release showed 95.85% cumulative release over 16 h following zero-order kinetics (R² = 0.9529). Pharmacokinetic evaluation revealed Cmax of 10.33 ± 2.15 µg/mL at Tmax of 4.0 h, with AUC0-12 h of 59.48 ± 13.34 µg·h/mL. A strong linear correlation (R² = 0.9714) was established between <i>in vitro</i> release and<i> in vivo</i> absorption.</p><h3>Conclusion</h3><p>The F3 formulation demonstrated significant systemic absorption following oral administration, as confirmed by comparison with IP reference data. The robust IVIVC supports the predictive utility of <i>in vitro</i> release data for <i>in vi</i>v<i>o</i> performance, facilitating formulation optimization for IBD and colon cancer therapy.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149034932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Cuprous Oxide Nanoparticles Green-synthesized Using Artemisia dracunculus Extract on Cell-cycle Progression and Apoptosis in Bladder Cancer Cells 青蒿提取物绿色合成氧化亚铜纳米颗粒对膀胱癌细胞周期进程和凋亡的影响
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-22 DOI: 10.1007/s12247-026-11035-6
Junqing Gu, Qiang Zhang, Chunlin Tan, Zhongbo Du
{"title":"Effect of Cuprous Oxide Nanoparticles Green-synthesized Using Artemisia dracunculus Extract on Cell-cycle Progression and Apoptosis in Bladder Cancer Cells","authors":"Junqing Gu,&nbsp;Qiang Zhang,&nbsp;Chunlin Tan,&nbsp;Zhongbo Du","doi":"10.1007/s12247-026-11035-6","DOIUrl":"10.1007/s12247-026-11035-6","url":null,"abstract":"<div><p>Biogenically mediated cuprous oxide nanoparticles using herbal extracts possess potent anticancer properties across different cancer cell models. These biocompatible particles induce apoptosis while minimizing toxicity, suiting nanomedicine applications. In this research, the generated cuprous oxide nanoparticles were stabilized effectively by the <i>Artemisia dracunculus</i> aqueous extract. FT-IR, EDX, TEM, XRD, UV-Vis, and FE-SEM methods were used to characterize the produced Cu<sub>2</sub>O NPs@<i>Artemisia dracunculus</i>. Peaks at 2θ angles of 36°, 42°, and 61° depict the crystal planes (111), (200), and (220), respectively. In this investigation, the resulting particles (10–20 nm) were observed. The anti-bladder cancer potentials of the Cu<sub>2</sub>O NPs@<i>Artemisia dracunculus</i> may eradicate remarkably bladder cancer cells through the MTT examination. The bladder cancer cells viability has been shown to be impacted by Cu<sub>2</sub>O NPs@<i>Artemisia dracunculus</i>. The cytotoxicity value of Cu<sub>2</sub>O NPs@<i>Artemisia dracunculus</i> against the HUVEC (Normal) cells was so low and less than IC<sub>50</sub>. The IC<sub>50</sub> value of Cu<sub>2</sub>O NPs@<i>Artemisia dracunculus</i> was 17 µg/mL against the UM-UC-3 bladder cancer cells. Recent Cu<sub>2</sub>O NPs@<i>Artemisia dracunculus</i> suggests anti-human bladder cancer potential without high toxicity against the normal cells. The IC<sub>50</sub> value of Cu<sub>2</sub>O NPs@<i>Artemisia dracunculus</i> was 33 µg/mL against the DPPH free radicals, while the IC<sub>50</sub> value of BHT (as a drug control) was 18 µg/mL. The flow cytometry examination of the UM-UC-3 cancer cells indicated the reduction of G0/G1 and G2/M phases and progression the S phase. Cu<sub>2</sub>O NPs@<i>Artemisia dracunculus</i> reduced the level of colony formation and mRNA expression of Bcl2, while increased the levels of apoptosis, LDH release, and ROS and mRNA expression of Bax and P53. The research data showed the employing Cu<sub>2</sub>O NPs@<i>Artemisia dracunculus</i> benefits to treat bladder cancer in the in vitro condition.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149034933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Engineered Lipid–Polymer Hybrid Nanoparticles of Delafloxacin for Dry Powder Inhaler: Box-Behnken Design-Based Optimization, Physicochemical Characterization, and In Vitro Lung Deposition Study 用于干粉吸入器的德拉沙星工程脂-聚合物混合纳米颗粒:基于Box-Behnken设计的优化、理化表征和体外肺沉积研究
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-21 DOI: 10.1007/s12247-026-11067-y
Priti Bagade, Achal Kuranjekar, Purushottam Gangane, Md Ali Mujtaba, Gamal Osman Elhassan, Siham Abdoun, Turky Omar Asar, Ameeduzzafar Zafar
{"title":"Engineered Lipid–Polymer Hybrid Nanoparticles of Delafloxacin for Dry Powder Inhaler: Box-Behnken Design-Based Optimization, Physicochemical Characterization, and In Vitro Lung Deposition Study","authors":"Priti Bagade,&nbsp;Achal Kuranjekar,&nbsp;Purushottam Gangane,&nbsp;Md Ali Mujtaba,&nbsp;Gamal Osman Elhassan,&nbsp;Siham Abdoun,&nbsp;Turky Omar Asar,&nbsp;Ameeduzzafar Zafar","doi":"10.1007/s12247-026-11067-y","DOIUrl":"10.1007/s12247-026-11067-y","url":null,"abstract":"<div><h3>Background and Aim</h3><p>Delafloxacin (DLF) is a broad-spectrum fluoroquinolone antibiotic with activity against both Gram-positive and Gram-negative bacteria and potential application in the treatment of non-nosocomial pneumonia. This study aimed to develop and characterize DLF-loaded lipid–polymer hybrid nanoparticles (LPHNPs) formulated as a dry powder inhaler (DPI) for pulmonary delivery. </p><h3>Methods and Results</h3><p>LPHNPs were prepared using a single-emulsion solvent evaporation method and optimized through a three-factor, three-level Box–Behnken design. The optimized nanoparticles exhibited a particle size of 166 ± 1.98 nm, polydispersity index of 0.259 ± 0.006, zeta potential of -23.7 ± 2.4 mV, entrapment efficiency of 89 ± 1.02%, and drug loading of 20 ± 0.37%. The optimized LPHNPs were converted into dry powder formulations using spray drying and lyophilization techniques for enhanced aerosolization and pulmonary delivery performance. Solid-state characterization using Fourier transform infrared spectroscopy and differential scanning calorimetry confirmed drug encapsulation and compatibility with excipients, while X-ray diffraction indicated an amorphous nature of the formulations. Morphological analysis revealed smooth, spherical particles. In vitro release studies demonstrated an initial burst followed by sustained drug release. The DPI formulations showed excellent aerodynamic properties, including high fine particle fraction, low moisture content, and good flowability. Brunauer–Emmett–Teller analysis indicated high drug loading with low surface area, and accelerated stability studies confirmed formulation robustness over six months. </p><h3>Conclusion</h3><p>Overall, the developed DPI-based LPHNP system offers enhanced stability, sustained release, and improved lung deposition, indicating its promise as an effective and patient-friendly pulmonary delivery system for DLF.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149034815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intellectual Property Landscape of Soft Gelatin Capsule Dosage Forms: Patents, Limitations, and Strategies for Non-Infringing Formulation Development 软明胶胶囊剂型的知识产权景观:专利、限制和非侵权配方开发策略
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-21 DOI: 10.1007/s12247-026-11059-y
Senthilraja Kaliyamoorthy, A. T. Rajasekhar
{"title":"Intellectual Property Landscape of Soft Gelatin Capsule Dosage Forms: Patents, Limitations, and Strategies for Non-Infringing Formulation Development","authors":"Senthilraja Kaliyamoorthy,&nbsp;A. T. Rajasekhar","doi":"10.1007/s12247-026-11059-y","DOIUrl":"10.1007/s12247-026-11059-y","url":null,"abstract":"<div><h3>Purpose</h3><p>This review comprehensively examines the patent landscape for soft gelatin capsule (softgel) dosage forms, critically analyzes key patent claims and their inherent limitations, and proposes evidence-based strategies for developing non-infringing formulations.</p><h3>Methods</h3><p>A systematic search of the USPTO, EPO (Espacenet), and WIPO PatentScope databases was conducted for the period 1990–2025. More than 3,200 patent records were initially retrieved; approximately 950 were screened on title and abstract, and more than 420 were analyzed in full. Structured search terminology included IPC/CPC codes A61K, A61J, and B65D. Only granted patents and published applications with clearly defined claims were included for detailed analysis. FDA Orange Book listings and European Medicines Agency (EMA) Supplementary Protection Certificate (SPC) registers were reviewed as complementary regulatory sources. Patent status was verified using the USPTO Patent Full-Text Database, EPO Espacenet Register, and WIPO PatentScope as of March 2026.</p><h3>Results</h3><p>The softgel IP landscape contains multiple expired foundational patents and numerous active patents with narrow, specific claims. Key technical limitations — hydrophilic drug incompatibility, moisture sensitivity, gelatin crosslinking, and temperature-constrained processing — naturally restrict enforceable claim breadth. Strategic design-around approaches including excipient substitution, alternative non-gelatin shell polymers, seamless encapsulation technology, and novel LBDDS fill systems provide potential pathways toward FTO, subject to pharmaceutical and legal validation.</p><h3>Conclusion</h3><p>Generic and innovation-driven manufacturers may develop non-infringing softgel formulations through systematic patent landscaping combined with rational formulation design. Emerging technologies in nanotechnology, 3D printing, and bio-based shell materials offer substantial unclaimed IP space for proactive patent filing. All design-around strategies discussed herein represent scientific frameworks; independent legal counsel is essential before commercial implementation.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149034907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Micellar Systems with Hydrophobic Core-Stabilized Polyethyleneimine Enabling Time-Dependent Positive Zeta Potential Transformation for Enhanced Intestinal Mucopermeation and Cellular Uptake 疏水核心稳定的聚乙烯亚胺胶束系统使时间依赖的正Zeta电位转化增强肠道粘膜手术和细胞摄取
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-19 DOI: 10.1007/s12247-026-11052-5
Ahmad Saleh Malkawi
{"title":"Micellar Systems with Hydrophobic Core-Stabilized Polyethyleneimine Enabling Time-Dependent Positive Zeta Potential Transformation for Enhanced Intestinal Mucopermeation and Cellular Uptake","authors":"Ahmad Saleh Malkawi","doi":"10.1007/s12247-026-11052-5","DOIUrl":"10.1007/s12247-026-11052-5","url":null,"abstract":"<div><h3>Objective</h3><p>This study aimed to develop micelles (M) bearing polyethyleneimine (PEI)–stearic acid (SA) hydrophobic ionic complex (PEISA) loads with a zeta potential-changing property for effective intestinal mucopermeation and cellular uptake.</p><h3>Methods</h3><p>The ionic complex PEISA was formed at 3:1, 3:2, and 3:4 SA-to-PEI charge ratios and dissolved in Cremophor RH 40, Cremophor EL, and Labrasol. The resultant homogenous micellar mixtures were reconstituted in DMSO, diluted in physiological media, and examined regarding the nanosize, polydispersity index (PDI), and zeta potential using dynamic light scattering (DLS). Micellar biocompatibility using a resazurin assay and cellular uptake were checked over Caco-2 cells, whereas mucopermeation was evaluated using in vitro Transwell diffusion.</p><h3>Results</h3><p>The ionic complex PEISA significantly improved PEI solubility from 0 up to ~ 1.5 (<i>p</i> ≤ 0.01), ~ 4.5 (<i>p</i> ≤ 0.001), and ~ 5.5 (<i>p</i> ≤ 0.001) mg/mL in the lipophilic core of Labrasol, Cremophor EL, and Cremophor RH 40, respectively. DLS measured an average droplet size of ~ 16 nm with &lt; 0.3 PDI, proving uniformity and stability. At 1:200 and 1:100, micellar dilutions preserving &gt; 90% cell viability after 24 h proved biocompatibility. At 3:100 dilution, MPEISA (3:1) observed cell viability (20.74 ± 1.83%) significantly (<i>p</i> ≤ 0.001) lower than MPEISA (3:2) (65.35 ± 3.91%) and MPEISA (3:4) (75.92 ± 1.75%). The gradual zeta potential changes depicted over 180 min from − 7.90 mV up to + 1.80 mV for MPEISA (3:4), MPEISA (3:2), and MPEISA (3:1) showed a significant improvement in micellar mucopermeation (<i>p</i> ≤ 0.001) to 46 ± 3.96%, 56.90 ± 4%, and 62.16 ± 4.06% and micellar cellular uptake (<i>p</i> ≤ 0.001) to 70.69 ± 5.63%, 62.72 ± 1.57%, and 57.46 ± 0.76% after 4–5 h, respectively.</p><h3>Conclusion</h3><p>The gradual PEI cationic charge exposure from the micellar complex PEISA enabled a time-dependent shift in micellar zeta potential toward a positive value, leading to improved mucus permeation and enhanced cellular uptake.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148987108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书